News | July 16, 2008

GE Contrast Agent Unlikely to Cause Adverse Outcomes

July 17, 2008 - GE Healthcare’s iodixanol, an isosmolar contrast medium, shows lower incidence of elevated serum creatinine (SCr) or decreased glomerular filtration rate (GFR) than iopromide, according to a study written by a team of physicians and researchers at the Medical University of South Carolina, and published in “Radiology”, a peer-reviewed journal for the field of radiology.

The study included 117 patients with decreased renal function, defined as SCr>1.5 mg/mL or GFR

Fewer patients administered iodixanol showed an SCr increase of 25 percent or greater, 8.5 percent vs. 28 percent respectively. No patients in either group showed a contrast media related adverse event at the 30- or 90-day follow-up. There was a clinically-relevant GFR reduction of 5mL/min in significantly more patients in the iopromide group than in the iodixanol group; 42.3 percent vs. 24.1 percent.
The study concluded that while intravenous contrast material application in high-risk patients is unlikely to be associated with permanent adverse outcomes, SCr levels after contrast material administration are lower in the iodixanol group than in the iopromide group.

The authors noted their findings may differ from other recently published studies on the topic. According to the text of the study, “Our [the authors] systematic serial assessment of SCr level and GFR over 3 days after CM [contrast media] administration may have been more sensitive to detect SCr-level changes compared with the single sampling at a variable interval (48-72 hours) after contrast medium administration in the prior investigation. Considering that in most patients with decreased renal function, the SCr will peak in the first 72 hours after CM administration, multiple measures may provide greater accuracy regarding SCr dynamics.”

“This study confirms the favorable safety profile of iodixanol in patients undergoing CT scans who may be at-risk for nephropathy,” said Richard Vitti, M.D., associate director medical & professional services in GE Healthcare.

For more information: www.gehealthcare.com, http://radiology.rsnajnls.org/

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...